Humacyte (HUMA) closed at $0.54 on November 16, 2026, down 3.2% from the previous close, on volume of 2,982,335 shares (30-day average 6,050,814).
Data as of November 16, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the largest for 5, 30, 60 and 90 days
Globe Newswire (Mon, 16-Nov 8:00 AM ET)
Piper Sandler Sticks to Their Hold Rating for Humacyte (HUMA)
TipRanks (Mon, 16-Nov 7:25 AM ET)
Humacyte Earnings Call Signals Stronger Commercial Momentum
TipRanks (Sat, 14-Nov 11:20 PM ET)
TipRanks (Thu, 12-Nov 3:20 AM ET)
Humacyte Warned by Nasdaq as Sub-$1 Share Price Triggers 180-Day Delisting Risk
TipRanks (Thu, 12-Nov 1:01 AM ET)
Globe Newswire (Wed, 11-Nov 8:00 AM ET)
Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Humacyte (HUMA)
TipRanks (Wed, 11-Nov 7:31 AM ET)
Humacyte’s Improving Commercial Traction Supports Buy Rating Despite Liquidity Risks
TipRanks (Wed, 11-Nov 5:26 AM ET)
Barclays Keeps Their Hold Rating on Humacyte (HUMA)
TipRanks (Wed, 11-Nov 4:16 AM ET)
Globe Newswire (Tue, 10-Nov 7:00 AM ET)
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Humacyte trades on the NASDAQ stock market under the symbol HUMA.
As of November 16, 2026, HUMA stock price declined to $0.54 with 2,982,335 million shares trading.
HUMA has a beta of 2.56, meaning it tends to be more sensitive to market movements. HUMA has a correlation of 0.12 to the broad based SPY ETF.
HUMA has a market cap of $150.09 million. This is considered a Micro Cap stock.
Last quarter Humacyte reported $1 million in Revenue and -$.06 earnings per share. This beat revenue expectation by $240,000 and exceeded earnings estimates by $.02.
In the last 3 years, HUMA traded as high as $9.97 and as low as $.34.
The top ETF exchange traded funds that HUMA belongs to (by Net Assets): VTI, VXF, IBB, SCHA, VHT.
HUMA has underperformed the market in the last year with a return of -54.6%, while SPY returned +11.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in HUMA shares. However, HUMA has outperformed the market in the last 3 month and 2 week periods, returning -1.8% and +31.4%, while SPY returned -4.6% and -2.1%, respectively. This indicates HUMA has been having a stronger performance recently.
HUMA support price is $.51 and resistance is $.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HUMA shares will trade within this expected range on the day.